EU medicines agency not suited to perform device evaluations, says commission report
This article was originally published in RAJ Devices
A European Commission-mandated report on the performance of the European Medicines Agency points out that the agency, “at this stage, is not suited to perform [the] evaluation of all medical devices”1,2.
You may also be interested in...
Italian medicines agency chief Nicola Magrini recounts the problems AIFA faced and the lessons it learned through its work at the height of the coronavirus outbreak in Italy.
EU guidance offers high-level recommendations on the steps that clinical trial sponsors should take to assess the impact of COVID-19 on the quality and reliability of data being generated in ongoing studies. Early scientific advice is recommended if changes must be made to existing protocols or data analysis plans.
The COVID-19 pandemic has given a fresh impetus to the ongoing EU project on remote decentralized trials with more appetite for innovative approaches.